HRP20150987T1 - UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc) - Google Patents

UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc) Download PDF

Info

Publication number
HRP20150987T1
HRP20150987T1 HRP20150987TT HRP20150987T HRP20150987T1 HR P20150987 T1 HRP20150987 T1 HR P20150987T1 HR P20150987T T HRP20150987T T HR P20150987TT HR P20150987 T HRP20150987 T HR P20150987T HR P20150987 T1 HRP20150987 T1 HR P20150987T1
Authority
HR
Croatia
Prior art keywords
systemic sclerosis
image
treatment
ssc
prevention
Prior art date
Application number
HRP20150987TT
Other languages
English (en)
Inventor
Claudia Hirth-Dietrich
Peter Sandner
Johannes-Peter Stasch
Andreas Knorr
Georges Von Degenfeld
Michael Hahn
Markus Follmann
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102010021637A external-priority patent/DE102010021637A1/de
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of HRP20150987T1 publication Critical patent/HRP20150987T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (18)

1. Spojevi prema formulama (1) do (27) [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] naznačeni time da su za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc).
2. Spojevi prema formulama (1), (2), (3), (4), (5), (6), (7) i (27) naznačeni time da su za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc).
3. Spoj prema formuli (3) naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze.
4. Najmanje jedan spoj prema zahtjevu 1 do 3 naznačen time da je u kombinaciji s barem jednim inhibitorom PDE5 odabranim iz skupine koja sadrži: Tadalafil ((6R,12aR)-2,3,6,7,12,12a-Heksahidro-2-metil-6-(3,4-metilen - dioksifenil)pirazino(1',2':1,6)pirido(3,4-b)indol-1,4-dion), Vardenafil (2-(2-Etoksi-5-(4-etilpiperazin-1-il-1-sulfonil)fenil)-5-metil-7-propil-3H-imidazo (5,1-f) (1,2,4)triazin-4-on), Sildenafil (3-[2-etoksi-5-(4-metilpiperazin-1-il)sulfonil-fenil]-7- metil- 9-propil-2,4,7,8-tetrazabiciklo [4.3.0]nona -3,8,10-trien-5-on), Udenafil 5-[2-propiloksi-5-(1-metil-2-pirolidiniletilamidosulfonil)fenil]-metil-3-propil-1,6-dihidro-7H-pirazolo(4,3-d)pirimidin-7-on, Dasantafil 7-(3-Bromo-4-metoksibenzil)-1-etil-8-[[(1,2)-2-hidroksiciklopentil]amino]-3-(2-hidroksietil)-3,7-dihidro-1-purin-2,6-dion, Avanafil 4-{[(3-kloro-4-metoksifenil)metil]amino}-2-[(2S)-2-(hidroksimetil)pirolidin-1-il]-N-(pirimidin-2-ilmetil)pirimidin-5-karboksamid, Mirodenafil, Lodenafil, UK 369.003, UK 371.800, SLx 2101 od tvrtke Surface Logix, LAS 34179 Triazolo[1,2-]ksantin,6-metil-4-propil-2-[2-propoksi-5-(4-metilpiperazino)sulfonil]fenil ili soli, hidrati ili hidrati soli naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc).
5. Najmanje jedan spoj prema zahtjevu 1 do 3 u kombinaciji sa sildenafilom ili vardenafilom naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc).
6. Spojevi prema zahtjevu 1 do 5 su za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc), difuzne sistemske skleroze (dSSc), ograničene sistemske skleroze (lSSc), preklapajućeg tipa sistemske skleroze, nediferenciranog tipa sistemske skleroze, sistemske skleroze bez sklerodermije, fibroze kože, sklerodermije, nefrogene fibrozne dermopatije (NFD), nefrogene sistemske fibroze (NSF), stvaranja keloida.
7. Spojevi prema zahtjevu 1 do 5 naznačeni time da su za uporabu za prevenciju i/ili liječenje sistemske skleroze SSc uz popratnu fibrozu unutrašnjih organa, koji obuhvaćaju crijeva, pluća, bubrege i krvne žile.
8. Spojevi prema formulama (3), (4), (6), i/ili (7) naznačeni time da su za uporabu za prevenciju i/ili liječenje sistemske skleroze SSc.
9. Najmanje jedan spoj prema formulama (3), (4), (6) i/ili (7) u kombinaciji s vardenafilom ili sildenafilom naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze SSc.
10. Uporaba spoja prema zahtjevima 1-9 naznačena time da je za proizvodnju lijeka za prevenciju i/ili liječenje sistemske skleroze (SSc) koji sadrži učinkovitu količinu spoja prema zahtjevima 1 do 9.
11. Uporaba spoja prema zahtjevima 1-9 naznačena time da je za proizvodnju lijeka za prevenciju i/ili liječenje sistemske skleroze (SSc), difuzne sistemske skleroze (dSSc), ograničene sistemske skleroze (lSSc), preklapajućeg tipa sistemske skleroze, nediferenciranog tipa sistemske skleroze, sistemske skleroze bez sklerodermije, fibroze kože, sklerodermije, nefrogene fibrozne dermopatije (NFD), stvaranja keloida, koji sadrži učinkovitu količinu spoja prema zahtjevima 1 do 9.
12. Uporaba spoja prema zahtjevima 1-9 naznačena time da je za proizvodnju lijeka za prevenciju i/ili liječenje sistemske skleroze SSc uz popratnu fibrozu unutrašnjih organa, koji obuhvaćaju crijeva, pluća, bubrege i krvne žile koji sadrži učinkovitu količinu spoja prema zahtjevima 1 do 9.
13. Farmaceutska formulacija koja sadrži barem jedan spoj ili jednu kombinaciju prema zahtjevima 1 do 9 naznačena time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc).
14. Farmaceutska formulacija koja sadrži barem jedan spoj ili jednu kombinaciju prema zahtjevima 1 do 9 naznačena time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc), difuzne sistemske skleroze (dSSc), ograničene sistemske skleroze (lSSc), preklapajućeg tipa sistemske skleroze, nediferenciranog tipa sistemske skleroze, sistemske skleroze bez sklerodermije, fibroze kože, sklerodermije, nefrogene fibrozne dermopatije (NFD), stvaranja keloida.
15. Farmaceutska formulacija koja sadrži barem jedan spoj ili jednu kombinaciju prema zahtjevima 1 do 9 naznačena time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze SSc uz popratnu fibrozu unutrašnjih organa, koji obuhvaćaju crijeva, pluća, bubrege i krvne žile.
16. Komplet koji sadrži najmanje jedan stimulator i/ili aktivator sGC prema zahtjevima od 1 do 3 ili kombinacija prema zahtjevima od 4 do 5 naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc).
17. Komplet prema zahtjevu 16 naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc), difuzne sistemske skleroze (dSSc), ograničene sistemske skleroze (lSSc), preklapajućeg tipa sistemske skleroze, nediferenciranog tipa sistemske skleroze, sistemske skleroze bez sklerodermije, fibroze kože, sklerodermije, nefrogene fibrozne dermopatije (NFD), stvaranja keloida.
18. Komplet prema zahtjevima 16 i 17 naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze SSc uz popratnu fibrozu unutrašnjih organa, koji obuhvaćaju crijeva, pluća, bubrege i krvne žile.
HRP20150987TT 2010-05-26 2015-09-18 UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc) HRP20150987T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102010021637A DE102010021637A1 (de) 2010-05-26 2010-05-26 Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP10170413 2010-07-22
PCT/EP2011/058433 WO2011147810A1 (en) 2010-05-26 2011-05-24 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
EP11722786.8A EP2576548B1 (en) 2010-05-26 2011-05-24 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc)

Publications (1)

Publication Number Publication Date
HRP20150987T1 true HRP20150987T1 (hr) 2015-10-23

Family

ID=45003356

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150987TT HRP20150987T1 (hr) 2010-05-26 2015-09-18 UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)

Country Status (31)

Country Link
US (1) US10189856B2 (hr)
EP (1) EP2576548B1 (hr)
JP (1) JP5883852B2 (hr)
KR (1) KR101881174B1 (hr)
CN (1) CN103038232B (hr)
AU (1) AU2011257336B2 (hr)
CA (2) CA2800709C (hr)
CL (1) CL2012003281A1 (hr)
CR (1) CR20120597A (hr)
CY (1) CY1116703T1 (hr)
DK (1) DK2576548T3 (hr)
EA (1) EA030735B9 (hr)
ES (1) ES2549979T3 (hr)
HK (1) HK1183868A1 (hr)
HR (1) HRP20150987T1 (hr)
HU (1) HUE025162T2 (hr)
IL (1) IL223128A (hr)
MA (1) MA34249B1 (hr)
ME (1) ME02207B (hr)
MX (1) MX2012013574A (hr)
MY (1) MY170094A (hr)
NZ (1) NZ603799A (hr)
PL (1) PL2576548T3 (hr)
PT (1) PT2576548E (hr)
RS (1) RS54261B1 (hr)
SG (1) SG185690A1 (hr)
SI (1) SI2576548T1 (hr)
TN (1) TN2012000550A1 (hr)
UA (1) UA116521C2 (hr)
WO (1) WO2011147810A1 (hr)
ZA (1) ZA201208824B (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
ES2644781T3 (es) * 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos sustituidos y su uso
PE20151001A1 (es) 2012-09-07 2015-07-15 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
AP2015008670A0 (en) * 2013-02-21 2015-08-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
AU2014236719B2 (en) 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
CA2927420A1 (en) 2013-10-15 2015-04-23 Toa Eiyo Ltd. 4-aminomethylbenzoic acid derivative
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
CA2951337C (en) 2014-06-13 2022-08-23 Inventiva Ppar compounds for use in the treatment of fibrotic diseases
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
ES2784477T3 (es) 2014-07-22 2020-09-28 Boehringer Ingelheim Int Acidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
JP6748113B2 (ja) 2015-05-06 2020-08-26 バイエル・ファルマ・アクティエンゲゼルシャフト 全身性硬化症（ＳＳｃ）に付随する指潰瘍（ＤＵ）を治療するための単独のまたはＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤、ｓＧＣ活性化剤の使用
SI3325013T2 (sl) * 2015-07-23 2023-11-30 Bayer Pharma Aktiengesellschaft Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba
EP3359258A4 (en) * 2015-10-07 2019-08-21 AiViva Biopharma, Inc. COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROTIC SKIN DISEASES
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
KR20180095594A (ko) 2015-12-18 2018-08-27 노파르티스 아게 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도
US11357777B2 (en) 2016-02-01 2022-06-14 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018188590A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
CN108690016B (zh) * 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
MA53127A (fr) 2018-07-11 2021-05-19 Cyclerion Therapeutics Inc Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
CN111638329B (zh) * 2020-06-09 2021-06-01 南方医科大学 一种用于检测布鲁氏菌病elispot检测试剂盒及其应用
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
CN115160312B (zh) * 2022-06-29 2023-12-26 常州制药厂有限公司 一种维立西呱关键中间体及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380945A (en) 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO2000002851A1 (en) 1998-07-08 2000-01-20 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6538023B1 (en) 2000-09-15 2003-03-25 Tsuyoshi Ohnishi Therapeutic uses of green tea polyphenols for sickle cell disease
DE10054278A1 (de) * 2000-11-02 2002-05-08 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2433425A1 (en) * 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20050267032A1 (en) 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005016345A1 (de) 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047945A1 (de) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
EP1906957A1 (en) 2005-07-18 2008-04-09 Bayer HealthCare AG Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
CA2686906A1 (en) 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators, sgc activators and combinations for the treatment of urological disorders
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
US8455638B2 (en) 2007-09-06 2013-06-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) 2007-12-03 2009-07-17 Derivados de piridina activadores de guanilato ciclasa soluble
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2009143018A2 (en) * 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
EP2328895B1 (en) * 2008-09-16 2013-03-27 Proximagen Limited Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
SG172841A1 (en) 2009-01-17 2011-08-29 Bayer Schering Pharma Ag Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction
PT2421519T (pt) 2009-04-23 2017-01-26 Univ Zuerich Bloqueadores do recetor nmda para o tratamento de anemia falciforme
EP2512479B1 (en) * 2009-12-18 2016-03-30 Exodos Life Sciences Limited Partnership Compositions for treating peripheral vascular disease
JP6143461B2 (ja) 2010-02-05 2017-06-07 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ｓＧＣ刺激剤又はｓＧＣ活性化剤単独及びＰＤＥ５阻害剤と組合せた嚢胞性線維症処置
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途

Also Published As

Publication number Publication date
PL2576548T3 (pl) 2015-11-30
AU2011257336A1 (en) 2012-12-20
KR101881174B1 (ko) 2018-07-23
NZ603799A (en) 2014-10-31
KR20130116001A (ko) 2013-10-22
CA2955143C (en) 2020-02-11
WO2011147810A1 (en) 2011-12-01
SG185690A1 (en) 2012-12-28
JP2013526598A (ja) 2013-06-24
DK2576548T3 (en) 2015-09-28
RS54261B1 (en) 2016-02-29
ME02207B (me) 2016-02-20
JP5883852B2 (ja) 2016-03-15
TN2012000550A1 (en) 2014-04-01
US20140038956A1 (en) 2014-02-06
ZA201208824B (en) 2014-01-29
US10189856B2 (en) 2019-01-29
IL223128A (en) 2016-05-31
MY170094A (en) 2019-07-05
MA34249B1 (fr) 2013-05-02
CA2800709A1 (en) 2011-12-01
EA201291309A1 (ru) 2013-06-28
CY1116703T1 (el) 2017-03-15
EA030735B9 (ru) 2019-02-28
CR20120597A (es) 2013-03-11
SI2576548T1 (sl) 2015-11-30
EP2576548A1 (en) 2013-04-10
AU2011257336B2 (en) 2015-11-19
MX2012013574A (es) 2013-01-24
UA116521C2 (uk) 2018-04-10
ES2549979T3 (es) 2015-11-03
CN103038232A (zh) 2013-04-10
PT2576548E (pt) 2015-09-16
EA030735B1 (ru) 2018-09-28
CA2955143A1 (en) 2011-12-01
IL223128A0 (en) 2013-02-03
CL2012003281A1 (es) 2013-05-17
CA2800709C (en) 2017-04-04
CN103038232B (zh) 2016-01-20
HUE025162T2 (en) 2016-04-28
HK1183868A1 (zh) 2014-01-10
EP2576548B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
HRP20150987T1 (hr) UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
JP2013526598A5 (hr)
RU2007102847A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev
RS52730B (sr) Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
MX2018014116A (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil )pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirroli din-1-carboxamida y sales del mismo.
NZ598907A (en) Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
HRP20070534T3 (hr) Sol fosforne kiseline kao inhibitor dipeptidil peptidaze-iv
AU2011212521B2 (en) sGC stimulators or sGC activators alone and in combination with PDE5 inhbitors for the treatment of Cystic Fibrosis
NZ596185A (en) Imidazopyrazines for use as kinase inhibitors
MX2019011954A (es) Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
EP3291811B1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
RU2014151004A (ru) Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
EP4072548A4 (en) COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZINE-1-YL)PYRAZOLO[ 1,5-A]PYRIMIDINE ANALOGUES AS INHIBITORS BY KRAS
HK1154574A1 (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
AR062501A1 (es) Composiciones terapeuticas
JP2017515848A5 (hr)
RU2007147595A (ru) Производные индактерола и фосфодиэстеразные ингибиторы для лечения заболеваний дыхательных путей
EP3177627A1 (en) Organic compounds
MX2023002942A (es) Formas cristalinas de un inhibidor de kras g12c.
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)
AR044648A1 (es) Combinaciones terapeuticas
CA2677690A1 (en) Treatment of comorbid premature ejaculation and erectile dysfunction
ATE320247T1 (de) Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion